骨质疏松序贯治疗策略的系统综述与Meta分析
该系统综述与Meta分析纳入39项原始研究,评估骨质疏松序贯用药策略对骨密度和骨折结局的疗效。序贯策略中骨密度增幅最大者包括罗莫佐单抗后用地舒单抗或双膦酸盐、特立帕肽后用罗莫佐单抗或地舒单抗、以及双膦酸盐后用罗莫佐单抗。
要点
- 双膦酸盐后序贯1年罗莫佐单抗在腰椎、股骨颈和全髋均显示稳健的骨密度增益。
- 罗莫佐单抗后序贯1年地舒单抗在腰椎、股骨颈和全髋显示中等骨密度增益。
- 双膦酸盐后序贯1年特立帕肽在腰椎有显著骨密度增益,但髋部无显著增益。
核心结论
- 这些发现提供了严谨的证据总结,有助于指导骨质疏松患者的序贯药物选择。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed、Embase和Cochrane Library数据库,应用预设标准筛选相关原始研究,最终纳入39项原始研究。
主要发现
- 双膦酸盐后序贯1年罗莫佐单抗的骨密度变化汇总估计值为腰椎10.1%(95%CI 9.9-10.4)、股骨颈3.1%(95%CI 2.9-3.4)、全髋3.1%(95%CI 2.7-3.5)。
- 罗莫佐单抗后序贯1年地舒单抗的骨密度变化汇总估计值为腰椎4.0%(95%CI 1.2-6.7)、股骨颈2.2%(95%CI 0.5-3.8)、全髋2.8%(95%CI 0.8-4.9),特立帕肽转换至1年地舒单抗获得相似增益。
- 双膦酸盐后序贯1年地舒单抗在腰椎(3.5%,95%CI 2.8-4.2)、股骨颈(1.5%,95%CI 1.2-1.9)和全髋(2.1%,95%CI 1.8-2.3)均显示显著骨密度增益。
- 双膦酸盐转换至1年特立帕肽在腰椎显示显著骨密度增益(5.1%,95%CI 4.4-5.9),但髋部未显示显著增益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We performed a systematic review and meta-analysis of the efficacy of sequential osteoporosis treatment strategies. Sequential strategies resulting in the greatest BMD gain included romosozumab to denosumab or bisphosphonates; teriparatide to romosozumab or denosumab; and bisphosphonates to romosozumab. These findings can help guide sequential medication choice for patients with osteoporosis. PURPOSE: The purpose of this systematic review and meta-analysis was to evaluate the efficacy of sequential osteoporosis medication strategies on bone mineral density (BMD) and fracture outcomes. METHODS: Pubmed, Embase, and Cochrane Library databases were searched, and pre-specified criteria were applied to select relevant primary studies for inclusion in this systematic review and meta-analysis. RESULTS: Thirty-nine primary studies were included. Meta-analysis summary estimates for BMD change on the second medication in a treatment sequence showed robust BMD gain with bisphosphonates followed by 1 year of romosozumab at the lumbar spine (10.1%, 95% CI 9.9-10.4), femoral neck (3.1%, 95% CI 2.9-3.4), and total hip (3.1%, 95% CI 2.7-3.5). Moderate BMD gains were found with romosozumab followed by 1 year of denosumab, with summary estimates of 4.0% (95% CI 1.2-6.7) at the lumbar spine, 2.2% (95% CI 0.5-3.8) at the femoral neck, and 2.8% (95% CI 0.8-4.9) at the total hip; similar gains were found with teriparatide transitioned to 1 year of denosumab. Bisphosphonates followed by 1 year of denosumab resulted in significant BMD gain at the lumbar spine (3.5%, 95% CI 2.8-4.2), femoral neck (1.5%, 95% CI 1.2-1.9), and total hip (2.1%, 95% CI 1.8-2.3). However, bisphosphonates transitioned to 1 year of teriparatide resulted in significant BMD gain at the lumbar spine (5.1%, 95% CI 4.4-5.9) but not at the hip. CONCLUSION: These findings provide a rigorous summary of the evidence to guide sequential medication choice for patients with osteoporosis.
引用
- Nayak S, Greenspan SL. A systematic review and meta-analysis of sequential treatment strategies for osteoporosis. Osteoporos Int. 2025. PMID: 41105226. doi:10.1007/s00198-025-07717-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。